Does CGEN pay a dividend?

The cached stock data on this page does not show a positive dividend yield for CGEN. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does CGEN stock do?

Clinical-stage immuno-oncology biotechnology firm utilizing a proprietary computational target discovery platform. The revenue model relies on non-recurring upfront and milestone licensing fees from major pharmaceutical partners (AstraZeneca, Bristol Myers Squibb, Bayer) alongside internal clinical pipeline development.

What is CGEN stock's price target?

This cached page does not contain a precise model fair value for CGEN.

The TradeMates model verdict for CGEN is HOLD with an investment score of 57/100. Treat this as a model signal to review, not a personal buy recommendation.

Is CGEN a good dividend stock?

CGEN is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

CGEN (CGEN) Stock Analysis

Q: Is CGEN stock a good investment?

The cached TradeMates AI model rates CGEN as HOLD with an investment score of 57/100. Compugen combines a sturdy $90.6M cash reserve with high clinical-stage execution risk, warranting a HOLD until pipeline readouts confirm commercial viability. This is algorithmic model output, not personal investment advice.

Verdict: HOLD

Milestone cash creates a $90.6M balance sheet shield, but lumpy licensing revenue and Phase 1/2 clinical binary risks cap visibility.

Investment score: 57/100

Compugen combines a sturdy $90.6M cash reserve with high clinical-stage execution risk, warranting a HOLD until pipeline readouts confirm commercial viability.

View the full interactive analysis